Key Details
Price
$25.31Annual Revenue
$872.00 MAnnual EPS
-$0.11PE Ratio
57.52Annual ROE
-7.18%Beta
2.12Events Calendar
Next earnings date:
Feb 26, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Even with a recent 30% drop in stock value, Hims & Hers Health, Inc. is still considered a "Strong Buy" because it is undervalued and has great long-term growth potential in the healthcare technology sector. The company's impressive performance in Q3 2024, highlighted by a 44% rise in subscribers and a 77% year-over-year revenue increase, shows its strong growth path. Additionally, management's improved revenue forecast for FY-2024 and new strategies, such as weight loss products and personalized services, enhance confidence in continued growth.
Hims & Hers Health (HIMS -3.93%) has experienced a lot of ups and downs in 2024. Following a recent drop, the stock has fallen over 25% from its peak.
Lately, users of Zacks.com have been very interested in Hims & Hers Health (HIMS). This interest prompts a closer look at what the stock might offer.
Hims & Hers Health is changing the telehealth industry with a unique approach that provides customized medications and has seen quick growth in subscriptions, which supports long-term profits. The company's financial performance is strong, showing a 40% increase in annual subscriptions and expected revenue growth of over 60% in 2024, suggesting it is still undervalued despite a 200% rise this year. Additionally, Hims & Hers is broadening its product range and using AI with MedMatch to improve treatment quality and customer satisfaction, strengthening its position in the market.
Hims & Hers stock has done very well this year as it keeps changing the healthcare market. The stock has increased by nearly 200%, while other companies in the sector, such as CVS Health and Walgreens Boots Alliance, have seen their prices drop.
Hims & Hers Health (HIMS -7.67%) shares are declining due to broader market trends and news related to GLP-1 medications. However, this company remains a growth stock that investors should keep an eye on, as Travis Hoium discusses in this video.
Hims & Hers Health Inc (NYSE:HIMS) shares are not participating in the overall market surge today, currently down 8.4% and priced at $26.15.
Lately, users of Zacks.com have been very interested in Hims & Hers Health (HIMS). This interest prompts a closer look at what the stock might offer.
Hims & Hers Health, Inc. (HIMS) has become a key player in the personalized healthcare sector, showing strong growth in 2024. In the last month, the company's shares have increased by 43%, which is much higher than the industry's growth of 5.5%.
Hims & Hers Health, Inc. has made notable progress in its key financial metrics, placing it alongside leading SaaS companies for growth and scalability. In the third quarter of FY2024, the company achieved an impressive 77% year-over-year revenue growth, thanks to a rise in subscribers and high retention in personal health services. Although there are regulatory challenges and competition, HIMS' innovative technology and emphasis on personalized healthcare create a solid base for long-term value for shareholders.
FAQ
- What is the primary business of Hims & Hers Health?
- What is the ticker symbol for Hims & Hers Health?
- Does Hims & Hers Health pay dividends?
- What sector is Hims & Hers Health in?
- What industry is Hims & Hers Health in?
- What country is Hims & Hers Health based in?
- When did Hims & Hers Health go public?
- Is Hims & Hers Health in the S&P 500?
- Is Hims & Hers Health in the NASDAQ 100?
- Is Hims & Hers Health in the Dow Jones?
- When was Hims & Hers Health's last earnings report?
- When does Hims & Hers Health report earnings?
- Should I buy Hims & Hers Health stock now?